Bioprinted liver tissue containing both parenchymal and non-parenchymal cells in spatially controlled, user-defined geometries that reproduce compositional and architectural features of native tissue are making it possible to assess drug effects over timeframes much longer than those offered by 2D liver cell culture systems.

CSL (ASX:CSL) has launched a trial of CSL112 in patients at risk of recurrent cardiovascular events and presented data into the cholesterol-clearing mechanism of action behind the drug. [ + ]

Genetic Technologies (ASX:GTG) has completed the sale of its Australian genetics business to Specialist Diagnostics Services as part of its streamlining efforts. [ + ]

Researchers at ETH Zurich have created the first gene network to be operated via brainwaves. Depending on the user's thoughts, it can produce various amounts of a desired molecule.

In March 2004, the spacecraft Rosetta was launched by the European Space Agency - its mission to orbit and land on the comet 67P/Churyumov-Gerasimenko. To complete the most detailed study of a comet ever attempted, the orbiter carried 11 science experiments and its lander, Philae, carried 10 additional instruments. [ + ]

Alchemia (ASX:ACL) has announced the sudden departure of CEO Thomas Liquard, Calzada (ASX:CZD) has appointed a new CEO and Patrys (ASX:PAB) has added to its board. [ + ]

An international research collaboration has built a pathway that makes brain-to-brain communication possible - with a little help from the internet. [ + ]

CSL (ASX:CSL) has completed a debt placement worth nearly $500m to help pay for capital management activities including its $900m share buyback. [ + ]

With Novogen (ASX:NRT) moving to take anticancer candidate Cantrixil into the clinic, the company is making moves to line up funding and allow it to better focus on clinical development. [ + ]

Innate Immunotherapeutics (ASX:IIL) is dosing patients in a phase IIb trial of its MIS416 candidate in secondary progressive multiple sclerosis, and plans to activate a third site tomorrow. [ + ]

Bionomics (ASX:BNO) has secured approval for a phase Ib trial of anxiety and depression drug candidate BNC210, and will soon apply to conduct a phase II trial in anxiety. [ + ]

Australian researchers have discovered how the massive DNA molecules that appear in some tumours are stitched together from other parts of the genome, making them similar to Frankenstein's monster. [ + ]

A study led by the Garvan Institute of Medical Research has shown why calcium-binding drugs commonly used to treat people with osteoporosis, or with late-stage cancers that have spread to bone, may also benefit patients with tumours outside the skeleton. [ + ]

Scientists from Orthocell and four universities have collaborated to grow viable human tendons in a laboratory for the first time. [ + ]

Medical technology company Rhinomed is using its BreatheAssist technology platform to develop nasal devices for sport, snoring, sleep apnoea and drug delivery. [ + ]